Ixekizumab Achieves 90.9 Percent Severity Reduction in Plaque Psoriasis, Suggests Study

Although Interleukin-17 (IL-17) is a known mediator of psoriasis, and previous global trials established the efficacy of secukinumab and ixekizumab since their United States Food and Drug Administration (USFDA) approvals, a clinical gap existed due to the lack of Indian data following its November 2022 launch. Consequently, Dr. Abhishek De and colleagues from the Department of Dermatology, Calcutta National Medical College, Kolkata, evaluated this Immunoglobulin G4 (IgG4) monoclonal antibody's real-world safety and efficacy.

Therefore, the retrospective, 24-week study at Calcutta National Medical College evaluated 22 moderate-to-severe plaque psoriasis patients failing prior systemic therapies, administering a 160 mg ixekizumab loading dose followed by 80 mg maintenance doses. Researchers tracked clinical efficacy by assessing reductions in disease severity, body surface area involvement, and global physician assessment scores.

Key Clinical Findings of the Study Includes:

• Dramatic PASI Improvement: The study research demonstrated a 90.9% average reduction in disease severity, with mean scores falling from 30.82 ± 7.06 at baseline to 2.82 ± 3.12 at week 24.

• High Clearance Rates: The study analysis recorded that PASI 75 was achieved by 95.45% of patients at week 24 compared to just 13.6% at week 4, while PASI 90 and PASI 100 reached 68.18% and 27.27%, respectively.

• Significant BSA Reduction: The study data revealed that the average body surface area involvement plummeted from a baseline of 27.18 ± 8.05 to 1.41 ± 1.56 by the end of 24 weeks.

• Favorable sPGA Trends: The findings indicated that mean global assessment scores improved from 3.55 ± 0.51 to 0.73 ± 0.56, with 90.9% of patients achieving complete or near-complete clearance by week 20.

• Reassuring Safety Profile: The study evaluation reported that only 22.7% of patients experienced mild side effects, predominantly local injection-site reactions, with zero instances of tuberculosis flare or serious infections.

The results suggest that ixekizumab is a highly effective and safe real-world intervention for moderate-to-severe plaque psoriasis, enabling 95.45% of patients to achieve a 75% improvement by week 24. Furthermore, this clinical success was achieved with a low 22.7% rate of purely mild side effects, without any serious adverse events.

These real-world outcomes suggest that clinicians may consider this rapid-acting biological therapy to achieve substantial skin clearance even in patients with complex comorbidities like latent tuberculosis or hypertension.

While the evaluation is limited by its retrospective nature, a relatively short follow-up, and missing data on difficult-to-treat areas like the nails or scalp, future prospective randomized trials with longer surveillance are warranted to further clarify long-term remission and safety dynamics.

Reference

De A, Ahmed SK, Chakraborty D, Pal S. Real-world efficacy and safety of Ixekizumab in the treatment of psoriasis: A case-series from Indian sub-continent. Indian J Dermatol 2026;71:410-3.